Journey Medical (DERM) Stock Price, News & Analysis

Company Overview

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles. Journey Medical leverages an in-house commercial infrastructure, including a specialized sales force and key partnerships with pharmacies and distributors, to reach dermatology practices and healthcare providers nationwide.

Underpinning its growth strategy is an acquisition-driven approach that targets established, off-patent dermatology assets with stable prescription demand. The company’s management team, comprised of executives with deep experience in pharmaceutical marketing and specialty drug launches, continues to screen for complementary assets to expand its addressable market and enhance shareholder value.

Key Stats

• Today's Range: $7.04 to $7.21
• 50-Day Range: $6.92 to $8.54
• 52-Week Range: $3.54 to $8.90
• Volume: 11,154 shs
• Average Volume: 112,629 shs
• Market Capitalization: $188.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.17
• Consensus Rating: Moderate Buy

Journey Medical Stock Analysis - MarketRank™

Journey Medical scored higher than 47% of companies evaluated by MarketBeat, and ranked 637th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Journey Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Journey Medical has a consensus price target of $12.17, representing about 70.0% upside from its current price of $7.16.

Amount of Analyst Coverage

Journey Medical has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Journey Medical are expected to grow in the coming year, from ($1.02) to ($0.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Journey Medical is -18.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Journey Medical is -18.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Journey Medical has a P/B Ratio of 7.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.14% of the float of Journey Medical has been sold short.

Short Interest Ratio / Days to Cover

Journey Medical has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Journey Medical has recently decreased by 3.45%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Journey Medical does not currently pay a dividend.

Dividend Growth

Journey Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.14% of the float of Journey Medical has been sold short.

Short Interest Ratio / Days to Cover

Journey Medical has a short interest ratio ("days to cover") of 8.4.

Change versus previous month

Short interest in Journey Medical has recently decreased by 3.45%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.08

News Sentiment

Journey Medical has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Journey Medical this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for DERM on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

1 people have added Journey Medical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Journey Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.03% of the stock of Journey Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.25% of the stock of Journey Medical is held by institutions.

DERM Stock Analysis - Frequently Asked Questions

How have DERM shares performed this year?

Journey Medical's stock was trading at $3.91 at the beginning of 2025. Since then, DERM stock has increased by 83.0% and is now trading at $7.1550.

How were Journey Medical's earnings last quarter?

Journey Medical Corporation (NASDAQ:DERM) issued its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.09. The company had revenue of $15.01 million for the quarter, compared to analysts' expectations of $14.93 million. Journey Medical had a negative trailing twelve-month return on equity of 48.69% and a negative net margin of 15.49%.
Read the conference call transcript.

When did Journey Medical IPO?

Journey Medical (DERM) raised $39 million in an initial public offering (IPO) on Friday, November 12th 2021. The company issued 3,520,000 shares at $10.00-$12.00 per share.

Who are Journey Medical's major shareholders?

Journey Medical's top institutional shareholders include Wasatch Advisors LP (4.94%), Geode Capital Management LLC (1.13%), PVG Asset Management Corp (0.61%) and Opaleye Management Inc. (0.41%). Insiders that own company stock include Claude Maraoui, Ramsey Alloush, Lindsay A Md Rosenwald, Justin Adam Smith and Joseph Benesch.
View institutional ownership trends.

How do I buy shares of Journey Medical?

Shares of DERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Journey Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Journey Medical investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Meta Platforms (META), ServiceNow (NOW), Adobe (ADBE) and AppLovin (APP).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DERM
• Previous Symbol: NASDAQ:DERM
• CIK: 1867066
• Web: journeymedicalcorp.com
• Phone: 480-434-6670
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Journey Medical: $12.17
• High Price Target: $13.00
• Low Price Target: $10.50
• Potential Upside/Downside: +69.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.67 million
• Net Margins: -15.49%
• Pretax Margin: -15.28%
• Return on Equity: -48.69%
• Return on Assets: -11.26%

Debt

• Debt-to-Equity Ratio: 1.11
• Current Ratio: 1.27
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: $56.40 million
• Price / Sales: 3.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.91 per share
• Price / Book: 7.88

Miscellaneous

• Outstanding Shares: 26,310,000
• Free Float: 22,356,000
• Market Cap: $188.64 million
• Optionable: N/A
• Beta: 0.80